
CorMedix (CRMD) Stock Forecast & Price Target
CorMedix (CRMD) Analyst Ratings
Bulls say
Cormedix is supported by a compelling mix of resilient current cash generation and credible long-term diversification, even as DefenCath faces reimbursement and pricing volatility after the 2Q27 reset. The company’s 3Q26 results showed DefenCath revenue of $17M, Melinta revenue of $31M to $37.3M, and cash of about $355M, while management reiterated FY26 revenue of $325M to $345M and narrowed adjusted EBITDA to $130M to $140M, reinforcing near-term financial stability. Its outlook improves further as Rezzayo’s 1Q27 Priority Review, the planned 1Q27 Heron close, and potential Medicare Advantage contracting create multiple paths to offset DefenCath uncertainty and broaden the revenue base.
Bears say
Cormedix is facing a weakening fundamental outlook because DefenCath’s growth story is increasingly constrained by slow clinical enrollment, regulatory uncertainty, and a narrowing set of expansion opportunities, including the removal of TPN from valuation after an uncertain development path. Commercially, 3Q26 revenue fell to $54.5MM, while DefenCath sales of $17.2MM were below expectations after TDAPA, and management suspended 2027 guidance pending clearer visibility on pricing, utilization, and Medicare Advantage contracting. The bearish view is reinforced by concentration risk, potential pricing pressure from the 2026 TDAPA cliff, competition from generics, and the possibility that the company may need additional funding before sustainable profitability.
This aggregate rating is based on analysts' research of CorMedix and is not a guaranteed prediction by Public.com or investment advice.
CorMedix (CRMD) Analyst Forecast & Price Prediction
Start investing in CorMedix (CRMD)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About CorMedix (CRMD) Forecast
CorMedix (CRMD) Analyst Forecast & Price Prediction
Start investing in CorMedix (CRMD)
Order type
Buy in
Order amount
Est. shares
0 shares